对比增强磁共振成像的信号增强率：胆管癌肝动脉灌注化疗后生存的潜在生物标志物。
Signal enhancement ratio of CE-MRI: a potential biomarker of survival after hepatic arterial infusion chemotherapy in biliary tract cancers.
作者信息
Zheng Kanglian, Fu Shijie, Leng Boyu, Cui Yong, Yang Renjie, Cao Guang, Xu Liang, Li Wen-Qing, Li Ying, Zhu Xu, Gao Song, Liu Peng, Wang Xiaodong
机构信息
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Interventional Therapy, Peking University Cancer Hospital & Institute, 52 Fucheng Road, Haidian District, Beijing, China.
Hebei North University, 11 Zuanshi South Road, Gaoxin District, Zhangjiakou, Hebei, China.
出版信息
Insights Imaging. 2022 Mar 14;13(1):46. doi: 10.1186/s13244-022-01188-6.
BACKGROUND
The association of contrast-enhanced MRI (CE-MRI) and the overall survival (OS) of biliary tract cancers (BTC) is ambiguous. Thus, the aim of this study is to evaluate the value of signal enhancement ratio (SER) and its early change in CE-MRI as biomarkers of survival after hepatic arterial infusion chemotherapy (HAIC) in BTC.
RESULTS
One hundred and two BTC patients treated via HAIC with 3cir-OFF regimen between January 2011 and June 2020 were enrolled in this retrospective study. The median progression-free survival (PFS) and OS were 9.8 months [range 1.5-83.3 months, 95% confidence interval (CI) 7.789-11.811] and 14.2 months (range 1.8-83.3 months, 95% CI: 11.106-17.294), respectively. The cutoff value of SER before HAIC (SER) was 1.04, and both median PFS and OS in the SER ≥ 1.04 group were longer than in the SER < 1.04 group (median PFS: 10.5 vs. 8.5 months, p = 0.027; median OS: 23.9 vs. 12.3 months, p < 0.001). The median OS in the ΔSER > 0 group was longer than in the ΔSER < 0 group (17.3 versus 12.8 months, p = 0.029 (ΔSER means the change of SER after two cycles of HAIC). Multivariate analysis showed SER (p = 0.029) and HAIC treatment cycle (p = 0.002) were independent predictors of longer survival.
CONCLUSIONS
SER in CE-MRI before HAIC (SER) is a potential biomarker for the prediction of survival after HAIC in advanced BTC.
背景
对比增强磁共振成像（CE-MRI）与胆道癌（BTC）的总生存期（OS）之间的关联尚不明确。因此，本研究旨在评估CE-MRI中的信号增强率（SER）及其早期变化作为BTC肝动脉灌注化疗（HAIC）后生存生物标志物的价值。
结果
本回顾性研究纳入了2011年1月至2020年6月期间接受HAIC联合3cir-OFF方案治疗的102例BTC患者。中位无进展生存期（PFS）和OS分别为9.8个月[范围1.5 - 83.3个月，95%置信区间（CI）7.789 - 11.811]和14.2个月（范围1.8 - 83.3个月，95% CI：11.106 - 17.294）。HAIC前SER的截断值为1.04，SER≥1.04组的中位PFS和OS均长于SER<1.04组（中位PFS：10.5个月对8.5个月，p = 0.027；中位OS：23.9个月对12.3个月，p < 0.001）。ΔSER>0组的中位OS长于ΔSER<0组（17.3个月对12.8个月，p = 0.029（ΔSER表示HAIC两个周期后SER的变化）。多因素分析显示SER（p = 0.029）和HAIC治疗周期（p = 0.002）是生存期延长的独立预测因素。
结论
HAIC前CE-MRI中的SER是预测晚期BTC患者HAIC后生存的潜在生物标志物。
Zotero 插件